Clinical trials: Lung Carcinoma
Anemia, Multiple Myeloma
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in reducing or preventing the need for transfusions in anemic patients with cancer receiving chemotherapy, and to investigate…
- Conditions
- Anemia, Multiple Myeloma, Lymphoma, Breast Cancer
- Trial name
- NCT00270166
- Testing
- epoetin alfa
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mesotheliomas Pleural
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%.
- Trial name
- PEMMELA (NCT04287829)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- Netherlands
- Volunteers
- 58 people
- Sponsor
- The Netherlands Cancer Institute
Cancer
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Heat shock protein 90 (Hsp90) is a chemical in the body that is involve in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
- Trial name
- NCT01892046
- Testing
- SNX-5422
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Esanex Inc.
Lung Cancer
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Multi-site randomized trial of the THRIVE digital health application versus usual care to evaluate the effect of THRIVE on quality of life (QOL), physical and psychological symptoms, coping, and self-efficacy in 250 patients with…
- Trial name
- THRIVE (NCT06427954)
- Testing
- Digital Health App
- Where
- 3 sites in United States
- Volunteers
- 250 people
- Sponsor
- Massachusetts General Hospital
Smoking Cessation
Bio-behavioral Lung Cancer Prevention Program
The overall goal of this research is to increase our understanding of the role of individual genetic differences in response to bupropion treatment and the psychobiological mechanisms by which genetic and treatment factors…
- Trial name
- NCT00322205
- Testing
- zyban
- Where
- United States
- Volunteers
- 555 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health (NIH)
NSCLC (Advanced Non-small Cell Lung Cancer)
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.
- Trial name
- NCT07609251
- Testing
- SCTB41, docetaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sinocelltech Ltd.
Non Small Cell Lung Cancer
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer
This study is designed to assess the effects of adding nitroglycerin (NTG) patches, delivery 25 mg NTG per 24 h, to the standard first line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC), i.e.
- Trial name
- NVALT12 (NCT01171170)
- Testing
- carboplatin paclitaxel bevacizumab, Standard treatment plus nitroglycerin
- Where
- 8 sites in Netherlands
- Volunteers
- 223 people
- Sponsor
- Dutch Society of Physicians for Pulmonology and Tuberculosis
Adenocarcinoma of the Lung, Large Cell Lung Cancer
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00087412
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
This randomized phase I/II trial is studying the side effects and best dose of cixutumumab and to see how well erlotinib hydrochloride works when given together with or without cixutumumab in treating patients with stage III or…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00778167
- Testing
- cixutumumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer
- Trial name
- NCT00350792
- Testing
- pemetrexed, carboplatin
- Where
- 7 sites in France
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Ventricular Failure
Right Ventricular Inflammation After Lung Resection
The purpose of this study is explore the impact of lung cancer surgery on inflammation and function of the right side of the heart.
- Trial name
- NCT03523611
- Testing
- Lung Resection
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- University of Glasgow
Non-small Cell Lung Cancer, Radiation Toxicity
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
Despite the growing interest in investigating how the radiotherapy (RT) dose to anatomical substructures of the heart links to survival, the heart substructures at risk remain poorly defined.
- Conditions
- Non-small Cell Lung Cancer, Radiation Toxicity, Cardiac Toxicity
- Trial name
- NCT04867564
- Testing
- Echocardiography
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Military Institute od Medicine National Research Institute
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
- Trial name
- KYLIN-1 (NCT06343064)
- Testing
- Vebreltinib, PLB1004
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Colorectal Cancer, High Grade Serous Ovarian Cancer
A Phase I Trial of LY3143921 Hydrate in Solid Tumours
This clinical study looked at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims were to find out the maximum dose of LY3143921 hydrate that could be given safely to…
- Conditions
- Colorectal Cancer, High Grade Serous Ovarian Cancer, Non Small-cell Lung Cancer (Squamous Cell Variant), Urothelial Cancer
- Trial name
- NCT03096054
- Testing
- LY3143921 hydrate
- Where
- 4 sites in United Kingdom
- Volunteers
- 69 people
- Sponsor
- Cancer Research UK
Carcinoma, Non-Small-Cell Lung
Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option
This is a monocentric prospective observational study. This study will include patients with a diagnosis of non-small cell lung cancer for the collection of blood and tissue specimens.
- Trial name
- Chewbacca (NCT06922266)
- Volunteers
- 20 people
- Sponsor
- Ospedale San Raffaele
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
ATM Gene Mutation, ATR Gene Mutation
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation
- Trial name
- NCT03377556
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Where
- 1,157 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma, Non-Small Cell Lung
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
- Trial name
- ARTEMIDELung04 (NCT06868277)
- Testing
- Rilvegostomig, Pembrolizumab
- Where
- 304 sites in United States, Argentina and 25 more
- Volunteers
- 830 people
- Sponsor
- AstraZeneca
Lung Adenocarcinoma
Blood Detection of EGFR Mutation For Iressa Treatment
This study was proposed to validate the efficacy of gefitinib as first-line therapy in advanced lung adenocarcinoma with EGFR mutation determined by plasma cf-DNA.
- Trial name
- Benefit (NCT02282267)
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer, Cancer
Vinorelbine and XR9576 to Treat Cancer
Tumor resistance to anti-cancer drugs is a major problem in cancer treatment. Studies have found that a protein (P-glycoprotein) on some cancer cells pumps chemotherapy drugs out of the cells, reducing treatment effectiveness.
- Conditions
- Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00001944
- Testing
- Vinorelbine, XR9576
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)